Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon antibody-mediated
disease of the central nervous system. Long segments of spinal cord inflammation (myelitis), …

Importance Antibodies to myelin oligodendrocyte glycoprotein IgG (MOG-IgG) are increasingly
detected in patients with non–multiple sclerosis–related demyelination, some of whom …

Pathogenic antibodies targeting the aquaporin-4 water channel on astrocytes are
associated with relapsing inflammatory neuromyelitis optica spectrum disorders. The clinical …

Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been described in patients
with neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 antibodies (…

Objective To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse
rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). …

Background and Objectives To evaluate the long-term safety and efficacy of tocilizumab (TCZ),
a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–…

Objective To define the frequency, duration, and severity of intractable nausea, vomiting, or
hiccups in aquaporin-4–immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica …

Neuromyelitis optica spectrum disorders (NMOSDs) are caused by immunoglobulin G (IgG)
autoantibodies directed against the water channel aquaporin-4 (AQP4). In NMOSDs, …

Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in
neurological disorders and there are no treatment guidelines. However, as a rapidly acting, …

Objective To identify factors predictive of relapse risk and disability in myelin oligodendrocyte
glycoprotein associated disease (MOGAD). Setting Patients were seen by the …